

Antiandrogen Flutamide Might Protect Multi-Generations of Rats from Androgen-Dependent Toxicity in Spinal and Bulbar Muscular Atrophy Induced by Benomyl or Carbendazim

Shui-Yuan Lu* and Wei-Ren Tsai

Taiwan Agricultural Chemicals and Toxic Substances Research Institute, Council of Agriculture, Taiwan, Republic of China

*Corresponding Author: Shui-Yuan Lu, Taiwan Agricultural Chemicals and Toxic Substances Research Institute, Council of Agriculture, Executive Yuan, Taichung, Taiwan, Republic of China.

Received: May 01, 20209; Published: May 30, 2020

As we all knew that carbendazim is a systemic fungicide for crops [1]. Carbendazim and its parent precursor fungicide, benomyl (Figure 1), exhibited low acute toxicity with oral LD₅₀ in male rats greater than 15 g/kg [2]. In contrary to the low acute toxicity, carbendazim and its parent compound benomyl showed reproductive toxicity in rodents [3-6]. Carbendazim and benomyl produced male reproductive toxicity, such as testicular disfunction by inducing the sloughing of germ cells [7,8], testicular toxicity [9], testicular lesion [10] and sterility [11].

In the respect of developmental toxicity, carbendazim and benomyl induced significant toxicity. Prenatal administration of carbendazim to rats during pregnancy produced exencephaly, microphthalmia and hydronephrosis in offspring [3,12]. Benomyl produced malformations such as cleft palate, exencephaly in prenatal developmental study [13]. In the co-treatment study with carbendazim and flutamide for 28 days, testicular weight, losses of spermatozoa concentration and cell morphology induced by carbendazim can be recovered by flutamide. Carbendazim induced androgen receptor related abnormalities including incomplete development of uterine horn, detention of urethra, disappearance of vagina and induction of extra seminal vesicles in female offsprings. Also, benomyl produced androgen receptor related malformations such as incomplete development, disappearance of vagina in female rats, testis and epididymis atrophy in male rats. Treatment with a longer duration, carbendazim induced androgen receptor expression with dose dependent manner in testis and epididymis. The *in vivo* results of androgen receptor expression was confirmed by carbendazim binding to androgen receptor with concentration dependent *in vitro* with testis extracts. We have showed that carbendazim-induced reproductive and developmental malformations are relieved by flutamide. This implied that androgen receptor-mediated reproductive and developmental toxicity induced by carbendazim [14]. Later, we further studied the endocrine disrupting endpoints with co-treatment carbendazim and flutamide to examine if the block effect will be significant. The results showed that the increased anogenital distance (AGD) in utero exposure carbendazim or benomyl in male pups were recovered by flutamide [15].

In order to prove that carbendazim-induced androgen receptor expression antagonized by flutamide in male rats we carried out the next study. We studied the androgen receptor expression in the mRNA and protein level with Western blot and activity with immunohistochemistry. Carbendazim induced androgen receptor expression of mRNA and protein with dose and time dependent and immune activity in testes of rats. All these endpoints can be recovered by flutamide treatment [16].

Though, anogenital distance is a representative endpoints of endocrine disrupting activity (EDA) so far two of standard protocol for endocrine disturb are uterotrophic assay (US EPA Series 890.1600) and Hershberger assay (US EPA Series 890.1400). We conduct these two protocols to study the expression of androgen receptor in a short-term treatment. The results showed that benomyl or carbendazim increased uterine weight in uterotrophic assay and weights of ventral prostate plus seminal vesicles through androgen receptor expression while flutamide can abolish the male accessory gland weight [17].

Based on above results we concluded that reproductive and developmental toxicity and endocrine disrupting activity induced by carbendazim or benomyl can be recovered by flutamide. Newly we found that carbendazim might induce spinal and bulbar muscular atrophy in multi-generation of rats [18].

Though we did not prove that flutamide can abolish the spinal and bulbar muscular atrophy in the multi-generation rats a report showed that prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy [19]. Four years later, another report confirmed that antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy [20]. In contrary to this result two reports showed that flutamide did not abrogate the SBMA through AR mediated in mice [21,22]. So far there is no reason for the difference between them. In spite of the difference of flutamide action, linking antagonistic effects of carbendazim and flutamide exposure in utero on reproductive and developmental toxicity in rats and androgen receptor expression antagonized by flutamide in male rats we are confident in flutamide abrogating the SBMA with supporting by Johansen, *et al.* (2020) [19] and Renier, *et al.* (2014) [20].

Based on chemical structure activity relationship we hypothesis that carbendazim and benomyl exhibited androgen receptor (AR) agonistic effect by sharing C and D ring with dihydrotestosterone (DHT) (Figure 1) while flutamide showed AR antagonistic effect by sharing A ring with DHT referred to the previous report by Tamura, *et al.* (2003) [23].




Figure 1: Schematic labeling of the benomyl, carbendazim mimic the main ligand interaction features of the natural ligand, dihydrotestosterone, with the androgen receptor.

Bibliography

1. Vettorazzi G. "State of the Art of the Toxicological Evaluation Carried Out by the Joint FAO/WHO Meeting on Pesticide Residues. II. Carbamate and Organophosphorus Pesticides Used in Agriculture and Public Health". *Residue Review* 63 (1976): 1-76.
2. Seiler JP. "Toxicology and genetic effects of benzimidazole compounds". *Mutation Research* 32.2 (1975): 151-168.
3. Cummings AM., et al. "Effects of methyl benzimidazole carbamate during early pregnancy in the rat". *Fundamental and Applied Toxicology* 15.3 (1990): 528-535.
4. Gray LE., Jr., et al. "Carbendazim-induced alterations of reproductive development and function in the rat and hamster". *Fundamental and Applied Toxicology* 15.2 (1990): 281-297.
5. Nakai M., et al. "Acute and long-term effects of a single dose of the fungicide carbendazim (methyl 2-benzimidazole carbamate) on the male reproductive system in the rat". *Journal of Andrology* 13.6 (1992): 507-518.
6. Perreault SD., et al. "Use of the fungicide carbendazim as a model compound to determine the impact of acute chemical exposure during oocyte maturation and fertilization on pregnancy outcome in the hamster". *Toxicology and Applied Pharmacology* 114.2 (1992): 225-231.
7. Parvinen M and Korman M. "Early effects of antispermatogenic benzimidazole derivatives U 32.422 and U 32.104 on the seminiferous epithelium of the rats". *Andrologia* 6.3 (1974): 245-253.
8. Hess RA., et al. "The fungicide benomyl (methyl-1-(butylcarbamoyl)-2-benzimidazolecarbamate) causes testicular dysfunction by inducing the sloughing of germ cells and occlusion of efferent ductules". *Fundamental and Applied Toxicology* 17.4 (1991): 733-745.
9. Lim J and Miller MG. "Role of testis exposure levels in the insensitivity of prepubertal rats to carbendazim-induced testicular toxicity". *Fundamental and Applied Toxicology* 37.2 (1997): 158-167.
10. Carter SD and Laskey JM. "Effect of benomyl on reproduction in the male rat". *Toxicology Letters* 11.1-2 (1982): 87-94.
11. Carter SD., et al. "The fungicide methyl 2-benzimidazole carbamate causes infertility in male Sprague-Dawley rats". *Biology of Reproduction* 37.3 (1987): 709-717.
12. Cummings AM., et al. "Developmental effects of methyl benzimidazole carbamate following exposure during early pregnancy". *Fundamental and Applied Toxicology* 18.2 (1992): 288-293.
13. Ellis WG., et al. "Benomyl-induced craniocerebral anomalies in fetuses of adequately nourished and protein-derived rats". *Teratogenesis Carcinogenesis and Mutagenesis* 7.4 (1987): 357-375.
14. Lu SY., et al. "Endocrine-disrupting activity in carbendazim-induced reproductive and developmental toxicity in rats". *Journal of Toxicology and Environmental Health, Part A* 67.19 (2004): 1501-1515.
15. Lu SY., et al. "Antagonistic and synergistic effects of carbendazim and flutamide exposures in utero on reproductive and developmental toxicity in rats". *Journal of Food and Drug Analysis* 14 (2006): 120-132.
16. Hsu YH., et al. "Carbendazim-induced androgen receptor expression antagonized by flutamide in male rats". *Journal of Food and Drug Analysis* 19 (2011): 418-428.
17. Lu SY., et al. "Detecting benomyl and its metabolite carbendazim inducing androgenic activity in rats by using uterotrophic and Hershberger assays". *Taiwanese Journal of Agricultural Chemistry and Food Science* 53 (2015): 235-250.

18. Lu SY and Tsai WR. "Benomyl- or carbendazim-induced androgen receptor disrupting might lead to spinal and bulbar muscular atrophy in multi-generations of rats". *Pharmaceutical Research* 4 (2020): 000198.
19. Johansen JA, et al. "Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy". *Neurodegenerative Diseases* 8.1-2 (2010): 25-34.
20. Renier KJ, et al. "Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy". *Neuroendocrinology* 155.7 (2014): 2624-2634.
21. Katsuno M, et al. "Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy". *Nature Medicine* 9.6 (2003): 768-773.
22. Katsuno M, et al. "Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives". *Journal of Molecular Medicine (Berlin)* 82.5 (2004): 298-307.
23. Tamura H, et al. "Interaction of organophosphate pesticides and related compounds with the androgen receptor". *Environmental Health Perspectives* 111.4 (2003): 545-552.

Volume 8 Issue 6 June 2020

©All rights reserved by Shui-Yuan Lu and Wei-Ren Tsai.